Advisory Alpha’s Gilead Sciences GILD Stock Holding History

Advisory Alpha’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$307K	Sell	2,430 -120	-5%	-$15.8K	0.01%	471
2026 Q1	$355K	Buy	2,550 +106	+4%	+$14.8K	0.01%	412
2025 Q4	$300K	Sell	2,444 -142	-5%	-$17.3K	0.01%	421
2025 Q3	$286K	Sell	2,586 -799	-24%	-$90.8K	0.01%	427
2025 Q2	$375K	Sell	3,385 -151	-4%	-$16.1K	0.01%	321
2025 Q1	$396K	Buy	3,536 +721	+26%	+$74.4K	0.01%	288
2024 Q4	$260K	Buy	+2,815	New	+$253K	0.01%	358
2020 Q4	–	Sell	-441	Closed	-$28K	–	303
2020 Q3	$28K	Buy	+441	New	+$30.6K	0.01%	278
2020 Q2	–	Sell	-515	Closed	-$40.1K	–	286
2020 Q1	$40.1K	Buy	515 +172	+50%	+$11.9K	0.01%	232
2019 Q4	$22.1K	Buy	343 +96	+39%	+$6.25K	0.01%	394
2019 Q3	$15.3K	Buy	+247	New	+$16.1K	﹤0.01%	404
2019 Q2	–	Sell	-883	Closed	-$58.4K	–	316
2019 Q1	$58.4K	Buy	+883	New	+$58.7K	0.02%	214

Other funds holding GILD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Advisory Alpha's GILD Position: Q2 2026 in Review

Advisory Alpha reduced its Gilead Sciences (GILD) stake by 4.7% in Q2 2026, selling an estimated $15.8K and leaving 2,430 shares worth $307K. The position accounts for 0.01% of the portfolio, ranked #471.

Advisory Alpha first reported a position in GILD in Q1 2019 and has held it in 12 quarters since. The position peaked at $396K in Q1 2025. 2,278 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

Advisory Alpha held 2,430 shares of Gilead Sciences worth $307K as of Q2 2026.
Advisory Alpha sold 120 Gilead Sciences shares in Q2 2026, an estimated $15.8K.
Gilead Sciences made up 0.01% of Advisory Alpha's portfolio in Q2 2026, its #471 holding.
Advisory Alpha first reported a position in Gilead Sciences in Q1 2019 and has held it in 12 quarters since.
Advisory Alpha's Gilead Sciences position peaked at $396K in Q1 2025.
2,278 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Advisory Alpha's 13F filing for Q2 2026, filed 11 Aug 2026.